Oxford BioMedica PLC
LSE:OXB

Watchlist Manager
Oxford BioMedica PLC Logo
Oxford BioMedica PLC
LSE:OXB
Watchlist
Price: 412.5 GBX -1.43% Market Closed
Market Cap: 434.6m GBX
Have any thoughts about
Oxford BioMedica PLC?
Write Note

Relative Value

The Relative Value of one OXB stock under the Base Case scenario is 718.92 GBX. Compared to the current market price of 412.5 GBX, Oxford BioMedica PLC is Undervalued by 43%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

OXB Relative Value
Base Case
718.92 GBX
Undervaluation 43%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
46
vs Industry
69
Median 3Y
3.2
Median 5Y
4.4
Industry
8.1
Forward
3.2
vs History
vs Industry
10
Median 3Y
-2.8
Median 5Y
-10.7
Industry
23
Forward
-10
vs History
vs Industry
4
Median 3Y
-6.3
Median 5Y
-6.9
Industry
23.4
vs History
vs Industry
8
Median 3Y
-3.7
Median 5Y
-5.4
Industry
27.3
vs History
22
vs Industry
19
Median 3Y
2.5
Median 5Y
5.3
Industry
2.6
vs History
44
vs Industry
59
Median 3Y
3.1
Median 5Y
4.4
Industry
8.1
Forward
3.4
vs History
38
vs Industry
42
Median 3Y
5.6
Median 5Y
10.4
Industry
9.6
vs History
vs Industry
15
Median 3Y
-7.2
Median 5Y
-9.1
Industry
4.3
Forward
-40
vs History
vs Industry
13
Median 3Y
-4.6
Median 5Y
-7.5
Industry
3.8
Forward
-11
vs History
vs Industry
4
Median 3Y
-6.7
Median 5Y
-7.2
Industry
6
vs History
vs Industry
11
Median 3Y
-7.4
Median 5Y
-13.4
Industry
3.8
vs History
50
vs Industry
44
Median 3Y
1.5
Median 5Y
3.2
Industry
4.8

Multiples Across Competitors

OXB Competitors Multiples
Oxford BioMedica PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Oxford BioMedica PLC
LSE:OXB
434.4m GBP 4.5 -3.1 -11 -6.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 563 478.2 -178 533.6 -216 796.7 -214 322.8
US
Abbvie Inc
NYSE:ABBV
300.2B USD 5.4 59.1 14.8 22.8
US
Amgen Inc
NASDAQ:AMGN
158.7B USD 4.9 37.5 17.5 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.8B USD 11.9 -264.2 26.8 28.1
US
Gilead Sciences Inc
NASDAQ:GILD
115B USD 4.1 912.5 10.1 10.1
US
Epizyme Inc
F:EPE
94.1B EUR 1 875.5 -478.6 -521.2 -507.3
AU
CSL Ltd
ASX:CSL
137.3B AUD 6 33.7 20.8 25.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
88.3B USD 6.4 19 17.4 19.4
US
Seagen Inc
F:SGT
39.3B EUR 18.1 -55.4 -59.5 -53.7
NL
argenx SE
XBRU:ARGX
34.1B EUR 18.5 -129.9 -104.5 -76.1
P/E Multiple
Earnings Growth
UK
Oxford BioMedica PLC
LSE:OXB
Average P/E: 212.4
Negative Multiple: -3.1
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -178 533.6 N/A
US
Abbvie Inc
NYSE:ABBV
59.1
412%
US
Amgen Inc
NASDAQ:AMGN
37.5
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -264.2
42%
US
Gilead Sciences Inc
NASDAQ:GILD
912.5
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -478.6 N/A
AU
CSL Ltd
ASX:CSL
33.7
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.4 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A
EV/EBITDA Multiple
EBITDA Growth
UK
Oxford BioMedica PLC
LSE:OXB
Average EV/EBITDA: 17.9
Negative Multiple: -11
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 796.7 N/A
US
Abbvie Inc
NYSE:ABBV
14.8
28%
US
Amgen Inc
NASDAQ:AMGN
17.5
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.8
38%
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.2 N/A
AU
CSL Ltd
ASX:CSL
20.8
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.4
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.5 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A
EV/EBIT Multiple
EBIT Growth
UK
Oxford BioMedica PLC
LSE:OXB
Average EV/EBIT: 23.2
Negative Multiple: -6.8
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -214 322.8 N/A
US
Abbvie Inc
NYSE:ABBV
22.8
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.1
44%
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -507.3 N/A
AU
CSL Ltd
ASX:CSL
25.9
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.4
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.1 N/A

See Also

Discover More
Back to Top